Abstract
This contribution outlines some of the key economic, social and ethical issues and dilemmas raised by the increasing interest in pharmacogenomics in psychiatric drug development in research and clinical settings.
Original language | English |
---|---|
Pages (from-to) | 80-82 |
Number of pages | 3 |
Journal | Psychiatry |
Volume | 6 |
Issue number | 2 |
DOIs | |
Publication status | Published - Feb 2007 |
Externally published | Yes |